Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine
Dengue
About this trial
This is an interventional prevention trial for Dengue focused on measuring Dengue Fever, Dengue Vaccine, Dengue Virus, Dengue Hemorrhagic Fever, Dengue Shock Syndrome
Eligibility Criteria
Inclusion Criteria:
- Good general health
- Available for the duration of the study (23 weeks for Cohort 1 and 32 weeks for Cohort 2)
- Willing to use acceptable forms of contraception for the duration of the study
Exclusion Criteria:
- Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease
- Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, may interfere with the study
- Significant laboratory abnormalities
- Medical, work, or family problems as a result of alcohol or illegal drug use within 12 months prior to study entry
- History of severe allergic reaction or anaphylaxis
- Severe asthma
- HIV-1 infected
- Hepatitis C virus (HCV) infected
- Hepatitis B surface antigen positive
- Known immunodeficiency syndrome
- Use of corticosteroids or immunosuppressive medications within 30 days prior to study entry. Individuals using topical or nasal corticosteroids are not excluded.
- Previous receipt of a live vaccine within 4 weeks prior to study entry
- Previous receipt of a killed vaccine within 2 weeks prior to study entry
- Absence of spleen
- Previous receipt of blood products within 6 months prior to study entry
- Previous receipt of dengue virus or other flavivirus (e.g., yellow fever virus, St.Louis encephalitis, West Nile virus) infection
- Previous receipt of yellow fever or dengue vaccine
- Plans to travel to an area where dengue infection is common
- Previous receipt of any investigational agent within 30 days prior to study entry
- Other condition that, in the opinion of the investigator, would affect participation in the study
- Pregnant or breastfeeding
Sites / Locations
- Center for Immunization Research, Johns Hopkins School of Public Health
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
1
2
3
Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.